Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Call Transcript October 30, 2024Neurocrine Biosciences, Inc. misses on earnings expectations.
Neurocrine Biosciences Inc (NBIX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 2,574,546 | $296,639,190 | +5% | 0.44% |
| 2. | AQR Capital Management Cliff Asness | 1,843,281 | $212,198,509 | +51% | 0.29% |
| 3. | Citadel Investment Group Ken Griffin | 1,764,590 | $203,316,060 | +139% | 0.03% |
| 4. | Deerfield Management James E. Flynn | 1,316,590 | $151,697,500 | +91% | 2.26% |
| 5. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 939,000 | $108,191,580 | -1% | 3.51% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.96 | 22,300 | Large Shareholder | 3,527,700 | 2011-10-12 | Filing | |
| $5.96 | 1,000 | Large Shareholder | 757,600 | 2011-10-12 | Filing | |
| $5.96 | 6,200 | Large Shareholder | 1,236,665 | 2011-10-12 | Filing | |
| $5.73 | 3,800 | Large Shareholder | 3,505,400 | 2011-10-11 | Filing | |
| $5.59 | 44,700 | Large Shareholder | 3,501,600 | 2011-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $113.66 | 1,295 | Officer | 377 | 2024-10-03 | Filing | |
| $121.88 | 3,461 | Officer | 1,672 | 2024-09-13 | Filing | |
| $146.69 | 14,250 | Director | 37,491 | 2024-08-15 | Filing | |
| $150.43 | 11,570 | Director | 119,047 | 2024-08-13 | Filing | |
| $150.38 | 14,100 | Officer | 31,528 | 2024-08-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,647,891 | $1,798,246,116 | 0.04% | |
| 2. | 9,710,328 | $1,279,432,817 | 0.02% | |
| 3. | 4,063,336 | $535,385,151 | 0.02% | |
| 4. | 2,430,500 | $320,242,680 | 4.89% | |
| 5. | 2,326,294 | $306,512,662 | 0.02% |
News See All
10 Most Promising Biotech Stocks According to Hedge Funds
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market.
10 Best Aggressive Growth Stocks to Buy According to Hedge Funds
If you're putting money in the stock market, it's more likely than not that growth is the thing that's on your mind.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2024 Earnings Call Transcript August 1, 2024Neurocrine Biosciences, Inc. misses on earnings expectations.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $0.4189 EPS, expectations were $1.04. Neurocrine Biosciences, Inc.
Insiders Are Dumping These 5 Healthcare Stocks
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) is a clinical stage biopharma company that is working on treatments for endocrine-related diseases.
5 Best Small-Cap Growth Stocks to Invest In
In this piece, we will take a look at the five best small-cap growth stocks to invest in.
Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks
In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2023 Earnings Call Transcript
Operator: Good day and welcome to Neurocrine Biosciences’ year-end and fourth quarter results call. At this time, all participants are in a listen-only mode.
Growth Stock Portfolio: 15 Companies with At Least 30% Annual Growth Rates
In this article, we will take a look at the 15 stocks with at least 30% annual growth rates to consider for a growth stock portfolio.
Billionaire Hedge Funds
